Sunday, November 8, 2026

GBP/EUR Went Down By Over 1% In The Last 10 Sessions

ViaNews Editorial Team

September 21, 2023

GBP/EUR Went Down By Over 1% In The Last 10 Sessions

(VIANEWS) - GBP/EUR (GBPEUR) has been up by 1.08% for the last 10 sessions. At 16:08 EST on Thursday, 21 September, GBP/EUR (GBPEUR) is $1.15.

GBP/EUR's yearly highs and lows, it's 6.64% up from its 52-week low and 2.039% down from its 52-week high.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, GBP/EUR's Forex is considered to be overbought (>=80).

News about

  • Usd/jpy hovers near yearly highs as investors await fed and boj decisions. According to FXStreet on Tuesday, 19 September, "The USD/JPY remains subdued as Tuesday's session begins, ahead of the US Federal Reserve's decision on Wednesday, in which the US central bank is expected to keep rates unchanged at the 5.25%-5.50% range. ", "Initial resistance for the USD/JPY is seen at 148.00 before climbing towards the October 31 daily high at 148.84. "
  • Usd/jpy hovers around 147.70, awaiting fomc’s decision. According to FXStreet on Wednesday, 20 September, "The USD/JPY remains subdued early in the North American session as traders brace for the US Federal Reserve's monetary policy decision. ", "From a technical perspective, the USD/JPY is at the brisk of conquering 148.00 and extends its gains towards the October 31 daily high of 148.84, which, if cleared, the USD/JPY could re-test the 150.00 mark. "
  • Usd/jpy rallying into 148.00 on fed rate call, inflation outlook. According to FXStreet on Wednesday, 20 September, "The USD/JPY pair is catching a lift up the charts following the Federal Reserve's (Fed) rate call and inflation outlook update, pushing into fresh highs near the 148.00 handle as the Greenback (USD) catches a ride on rising inflation expectations from the Fed.", "Today's topside action for the USD/JPY has the pair set to challenge ten-month highs."
  • Usd/jpy May continue to trade higher – OCBC. According to FXStreet on Tuesday, 19 September, "With no imminent BoJ shift, markets could revert back to trading USD/JPY higher. ", "Beyond the near term, we expect USD/JPY to trade lower on the back of a moderate-to-soft USD profile (as Fed tightening stretches into late cycle and that USD can fall when pause or pivot comes into play) and on expectation for further BoJ shift towards policy normalisation amid higher inflationary and wage pressures in Japan."
  • Usd/jpy remains confined in a range below YTD top; awaits crucial fed, boj policy meetings. According to FXStreet on Tuesday, 19 September, "This, in turn, suggests that the path of least resistance for the USD/JPY pair is to the upside. ", "The outlook remains supportive of elevated US Treasury bond yields, which assists the US Dollar (USD) to stall its corrective pullback from a six-month peak and lends support to the USD/JPY pair."

More news about GBP/EUR (GBPEUR).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Season: Regulatory Deadlines and Data Readouts Against Cost Discipline and Slipping Timelines
From late October 2026 to January 2027, mid-cap biotechs cluster pivotal data presentations (ESMO, AHA, AASLD), FDA decision dates (ivonescimab BLA on 2026-11-14, lorundrostat on 2026-12-22) and Q3 earnings. Alongside these, several companies are managing capital: lowering R&D and SG&A guidance, pushing clinical milestones into 2027, authorizing a $400M buyback, and pursuing a delisting. Late-stage programs in oncology, hepatitis delta, hypertension and women's health look near commercial inflection, while cost cuts and delays point to uneven balance-sheet strength.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,552 source documents archived
Query this data → isubstrate.com